Skip to main content

Table 2 Annualized change In BMD

From: Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists

Group

Lumbar spine

Femoral neck

Control

0.4%

0.2%

Treated with CE + MPA

-2.9%†

-2.2%‡

Treated with CE + MT + MPA

0%

1.6%

  1. BMD was measured using quantitative digital radiography (Hologic Inc, Waltham, MA, USA). CE, conjugated estrogens; MPA, medroxyprogesterone acetate; MT, methyltestosterone. † P= 0.001, ‡ P = 0.006.